| Literature DB >> 29124205 |
Hitoshi Tanimukai1,2, Takashi Kudo3.
Abstract
Paclitaxel (Px) is an effective chemotherapeutic agent for the treatment of various cancers. However, it is often associated with neurological side effects, including chemotherapy-associated cognitive impairment (CACI), such as "chemobrain". Previously, we reported that endoplasmic reticulum (ER) stress is involved in Px-induced neurotoxicity, and immunoglobulin heavy chain binding protein (BiP) inducer X (BIX) alleviates Px-induced neurotoxicity. However, BIX has not been used in clinical practice yet. We recently reported that fluvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R). The purpose of this study was to investigate whether Flv could alleviate Px-induced neurotoxicity in vitro. SK-N-SH cells were pre-treated for 12 h with or without 10 μg/ml Flv followed by treatment with 1 μM Px with or without co-existence of 10 μg/ml Flv for 24 h. To investigate the involvement of Sig-1R in alleviation effect on Px-induced neurotoxicity,1 μM NE100, an antagonist of Sig-1R, was added for 24 h. Neurotoxicity was assessed using the MTS viability assay and ER stress-mediated neurotoxicity was assessed by evaluating the expression of C/EBP homologous protein (CHOP), cleaved caspase 4, and cleaved caspase 3. Pre-treatment with Flv significantly alleviated the induction of CHOP, cleaved caspase 4, and cleaved caspase 3 in SK-N-SH cells. At the same time, pre-treatment with Flv significantly induced Sig-1R in SK-N-SH cells. In addition, viability was significantly higher in Flv-treated cells than in untreated cells, which was reversed by treatment with NE100. Our results suggest that Flv alleviates Px-induced neurotoxicity in part through the induction of Sig-1R. Our findings should contribute to one of the novel approaches for the alleviation of Px-induced neurotoxicity, including chemobrain.Entities:
Keywords: BIX, BiP inducer X; BiP, immunoglobulin heavy-chain binding protein; CACI, chemotherapy-associated cognitive impairments; CHOP, C/EBP homologous protein; CYP, cytochrome P450; Chemobrain; ER, endoplasmic reticulum; Endoplasmic reticulum stress; Fluvoxamine; Flv, fluvoxamine; JNK, c-Jun NH2-terminal kinase; Paclitaxel; Px, paclitaxel; QOL, quality of life; SSRI, selective serotonin reuptake inhibitor; Selective serotonin reuptake inhibitor; Sig-1R, sigma 1 receptor; Sigma 1 receptor; UPR, unfolded protein response
Year: 2015 PMID: 29124205 PMCID: PMC5668922 DOI: 10.1016/j.bbrep.2015.09.014
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1Flv toxicity in SK-N-SH cells. Flv was added to SK-N-SH cells at the indicated dose. Cell toxicity was assessed using an MTS assay 24 h later. DDW was applied as the vehicle control. The relative ratio compared with the absorbance of the vehicle control (0 μM) is indicated. Histograms shows the mean±SD from six independent experiments. ⁎p<0.001 (Student's t-test).
Fig. 2Flv alleviates Px-induced ER stress-mediated apoptosis. (a–c) SK-N-SH cells were pre-treated with or without 10 μg/ml Flv for 12 h followed by a 1-μM Px treatment with or without 10 μg/ml Flv for 24 h. CHOP, caspase 4, and caspase 3 were detected by Western blotting. GAPDH was used as an internal control. ⁎p<0.05, ⁎⁎p<0.01 (one-way ANOVA followed by Tukey–Kramer test. (d and e) SK-N-SH cells were treated with 10 μg/ml Flv for 12 h and 24 h. Sig-1R was detected by Western blotting. GAPDH was used as an internal control. ⁎p<0.05, ⁎⁎p<0.01 (Student's t-test).
Fig. 3Flv alleviates Px-induced neurotoxicity through Sig-1R. SK-N-SH cells were pre-treated with or without 10 μg/ml Flv for 12 h followed by a 1 μM Px, 10 μg/ml Flv, and 1 μM Px/10 μg/ml Flv, with or without 1 μM NE100 treatment for 24 h. The viability was assessed using an MTS assay. The relative ratio of the absorbance compared with the vehicle control absorbance is indicated. Histograms show the mean±SD from six independent experiments. *p<0.05, **p<0.01 (one-way ANOVA followed by Tukey–Kramer test).